On November 3, 2021 ImmunoGenesis, a clinical-stage biotechnology company developing science-driven immune therapies, reported the acceptance of six poster presentations on its lead development programs at the Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper) 36th Annual Meeting (SITC 2021), which will be held November 10-14, 2021, in Washington, DC. Additional meeting information can be found on the SITC (Free SITC Whitepaper) website (Press release, ImmunoGenesis, NOV 3, 2021, View Source [SID1234594287]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Poster Presentation Details

Posters Related to IMGS-001: PD-L1/PD-L2 Dual-Specific Antibody with Effector Function

Title: Human PD-L2 triggers a unique T cell inhibitory program through PD-1 engagement distinct from that of PD-L1
Poster Number: 233
Date: November 12, 2021

Title: Dual-specific antibodies blocking both PD-L1 and PD-L2 engagement of PD-1 restore anti-tumor immunity
Poster Number: 291
Date: November 12, 2021

Posters Related to IMGS-501: STING Immune Stimulating Antibody Conjugate (STING-ISAC)

Title: High-potency synthetic STING agonists rewire the myeloid stroma in the tumor microenvironment to amplify immune checkpoint blockade efficacy in refractory pancreatic ductal adenocarcinoma
Poster Number: 758
Date: November 13, 2021

Title: Intratumoral delivery of high potency STING agonists modulates the immunosuppressive myeloid compartment and induces curative responses in checkpoint-refractory Glioblastoma models
Poster Number: 763
Date: November 12, 2021

Posters Related to Evofosfamide Hypoxia-Reversal Agent in Combination with Checkpoint Inhibitors

Title: Disrupted oxygen supply and tumor hyper- oxygen consumption contribute independently to prostate cancer immune privilege
Poster Number: 622
Date: November 13, 2021

Title: Hypoxia reduction in tandem with anti-angiogenic therapy remodels the PDAC microenvironment and potentiates CD40 agonist therapy
Poster Number: 730
Date: November 13, 2021

On November 3, 2021 Sumitomo Dainippon Pharma Oncology, Inc., a clinical-stage company focused on research and development for novel cancer therapeutics, reported that the first patient has been dosed in the Phase 1 dose expansion portion of the study evaluating the investigational agent TP-1287, an oral cyclin-dependent kinase 9 (CDK9) inhibitor, in patients with sarcoma (Press release, Sumitomo Dainippon Pharma, NOV 3, 2021, View Source [SID1234594286]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The Phase 1 open-label study consists of two parts, dose escalation and dose expansion. The dose escalation portion of the study established the maximum tolerated dose (MTD) and recommended Phase 2 Dose (RP2D) of TP-1287 in patients with advanced metastatic or progressive solid tumors. The dose expansion portion of the study will evaluate the potential antitumor activity and safety of TP-1287 in patients with Ewing sarcoma (EWS), dedifferentiated liposarcoma (DDLPS) and synovial sarcoma (SS).

"Patients with sarcoma currently face a significant unmet need and have limited treatment options. The dose expansion of TP-1287 provides an opportunity for us to evaluate this treatment and its potential benefits for this patient population," said Patricia S. Andrews, Chief Executive Officer, Global Head of Oncology, Sumitomo Dainippon Pharma Oncology, Inc (SDP Oncology). "Furthermore, this is an important step forward for our Phase 1 trial as we continue to evaluate TP-1287’s safety and efficacy."

The primary objective of the Phase 1 dose expansion portion of the study is to evaluate the preliminary antitumor activity of TP-1287 in terms of objective response rate (ORR) when administered at the RP2D in patients with sarcoma subtypes. The secondary objectives are to determine the progression-free survival (PFS), PFS rate at 16 weeks and PFS rate at 24 weeks following first administration of TP-1287 in patients with the defined sarcoma subtypes and evaluate the safety of TP-1287 when administered at the RP2D in patients with the defined sarcoma subtypes.

The study is being conducted at sites in the United States. Additional information on this trial, including comprehensive inclusion and exclusion criteria, can be accessed at www.ClinicalTrials.gov (NCT03604783).

About TP-1287

TP-1287 is an investigational oral CDK9 inhibitor that has shown favorable oral bioavailability in preclinical models. TP-1287 is enzymatically cleaved, yielding the active moiety, a potent inhibitor of CDK9.1 Inhibiting CDK9 is thought to downregulate the transcription of target genes, including MCL-1, reducing leukemic blast viability in MCL-1–dependent hematologic malignancies, and c-MYC, an important oncogene across multiple tumor types.2,3,4 TP-1287 is currently being evaluated in a Phase 1 study in patients with advanced solid tumors (NCT03604783).

On November 3, 2021 Insmed Incorporated Inc. (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, reported that management will participate in the following virtual investor conferences (Press release, Insmed, NOV 3, 2021, View Source [SID1234594285]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The Credit Suisse 30th Annual Virtual Healthcare Conference on November 9, 2021 at 10:30 a.m. ET in a fireside chat
The Stifel 2021 Virtual Healthcare Conference on November 17, 2021 at 8:40 a.m. ET in a fireside chat
The Evercore ISI 4th Annual HealthCONx Virtual Conference on November 30, 2021 at 8:00 a.m. ET in a fireside chat
Each fireside chat will be webcast live and can be accessed by visiting the investor relations section of the Company’s website at www.insmed.com. Each webcast will be archived for a period of 30 days following the conclusion of each live event.

On November 3, 2021 Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage biopharmaceutical company utilizing proprietary genetic engineering platform technologies to create cell and gene therapeutics with the capacity to cure, reported that the Company will participate in the following upcoming virtual investor conferences (Press release, Poseida Therapeutics, NOV 3, 2021, View Source [SID1234594284]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Stifel 2021 Virtual Healthcare Conference
Date: Tuesday, November 16, 2021
Time: 2:40pm ET

Piper Sandler 33rd Annual Virtual Healthcare Conference
Date: Monday, November 22, 2021
Time: Pre-record available at 10:00am ET

Webcasts will be available on the Investors & Media Section of the Poseida website, www.poseida.com. An archived replay of each webcast will be available for approximately 30 days following each presentation.

On November 3, 2021 EpiVax Therapeutics, Inc. ("EVT"), an emerging biotechnology company, reported that an abstract highlighting its Ancer platform will be presented at the upcoming Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper) 36th Annual Meeting from November 12-14, 2021 in Washington, DC (Press release, EpiVax, NOV 3, 2021, View Source [SID1234594283]). Details on the poster that will be presented as part of the regular submissions are below.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Title: Stealthier Mutanomes are Induced After Nivolumab Immunotherapy
Authors: Richard et. al
Poster #: 313
Presentation Date/Time: November 12, 2021, 7:00 am – 8:30 pm ET

The EpiVax Therapeutics Ancer platform will optimize precision immunotherapies development

"We are excited to share new research featuring the use of Ancer in novel biomarker identification. These new findings will optimize precision immunotherapies development at EpiVax Therapeutics," said Michael Princiotta, PhD, EpiVax Therapeutics CSO.